Stock comparison

BMYvsJAZZ

Bristol-Myers Squibb CovsJazz Pharmaceuticals PLC. Real data pulled from the alphactor.ai fundamentals pipeline — valuation, balance-sheet health, momentum, and analyst sentiment side by side.

BMY

Bristol-Myers Squibb Co

$59.02

+8.71%

Pharmaceuticals$117.4BNYSE

JAZZ

Jazz Pharmaceuticals PLC

$199.96

+17.95%

Pharmaceuticals$11.5BNASDAQ

60-day price, rebased to 100

BMY +8.73% · JAZZ +21.94%

Round-by-round

BMY 4·JAZZ 2

EdgeBMY

Valuation upside

+2.90% vs -5.90% to DCF fair value

EdgeBMY

Balance-sheet strength

Altman Z 2.20 vs 1.73

EdgeBMY

Fundamental quality

Piotroski 9.00 vs 5.00 (of 9)

EdgeJAZZ

Growth + margins

Rule-of-40 26.40 vs 31.70

EdgeJAZZ

60-day momentum

+8.73% vs +21.94% price return

EdgeBMY

Market-cap liquidity

$117.4B vs $11.5B

Verdict

Across6categories,BMYtakes the edge with4wins to2. Neither score is a buy signal on its own: run the full backtest and credibility tests on alphactor.ai before putting money on it.

Backtest a strategy onBMYorJAZZ

Point-in-time backtests, 8-layer credibility pipeline, conviction scoring — free to start.